Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.9%

119 terminated/withdrawn out of 1093 trials

Success Rate

85.3%

-1.2% vs industry average

Late-Stage Pipeline

9%

102 trials in Phase 3/4

Results Transparency

58%

403 of 693 completed trials have results

Key Signals

184 recruiting403 with results78 terminated41 withdrawn

Enrollment Performance

Analytics

N/A
544(57.1%)
Phase 2
172(18.1%)
Phase 1
90(9.5%)
Phase 4
58(6.1%)
Phase 3
44(4.6%)
Early Phase 1
44(4.6%)
952Total
N/A(544)
Phase 2(172)
Phase 1(90)
Phase 4(58)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1093)

Showing 20 of 1093 trials
NCT05812131Not ApplicableRecruiting

COPEWeb Training for Providers

Role: collaborator

NCT07567794Recruiting

GBPDC: Gut-Brain in PD Consortium Master Protocol

Role: collaborator

NCT07421102Early Phase 1Recruiting

Pilot of Mailing Buprenorphine

Role: lead

NCT05047172Phase 3Active Not Recruiting

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Role: collaborator

NCT03926520Not ApplicableCompleted

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

Role: collaborator

NCT04935606Not ApplicableCompleted

mHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care

Role: collaborator

NCT07179822Not ApplicableRecruiting

Motoneuron Recruitment and Motor Evoked Potential Up-Conditioning (MEP) in Spinal Cord Injury (SCI)

Role: lead

NCT00756769Recruiting

Systemic Lupus Erythematosus in Gullah Health

Role: lead

NCT04855032Not ApplicableCompleted

Post-stroke Perturbation Training

Role: lead

NCT04523922Phase 2Completed

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

Role: lead

NCT07242690Not ApplicableSuspended

PET-CT Imaging With PCD-CT

Role: lead

NCT05627596Phase 2Completed

Free Samples for Health

Role: collaborator

NCT07720167Phase 2Not Yet Recruiting

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

Role: lead

NCT06273436Not ApplicableRecruiting

Healing, Equity, Advocacy and Respect for Mamas

Role: lead

NCT05349682Not ApplicableActive Not Recruiting

Bayer OA Knee Pain Pilot

Role: lead

NCT07720180Phase 2Not Yet Recruiting

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

Role: lead

NCT06634823Early Phase 1Recruiting

Efficacy of Intramuscular Steroid Injection for Chronic Cough.

Role: lead

NCT06824649Phase 4Recruiting

Biologics in Chronic Rhinosinusitis With Nasal Polyposis

Role: lead

NCT05977439Not ApplicableRecruiting

RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS

Role: lead

NCT05896033Not ApplicableRecruiting

Impact of Cigarette and E-cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes

Role: lead